In8 Bio, Inc. financial data

Symbol
INAB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Empire State Building, 350 5 Th Avenue, Suite 5330, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Incysus Therapeutics, Inc. (to 9/20/2018)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 426 % -40.1%
Debt-to-equity 40.6 % +66.6%
Return On Equity -151 % -21.1%
Return On Assets -105 % -27.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.3 M shares +73.6%
Common Stock, Shares, Outstanding 43.3 M shares +76.4%
Common Stock, Value, Issued 4 K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 43.3 M shares +75%
Weighted Average Number of Shares Outstanding, Diluted 43.3 M shares +75%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 17.3 M USD +7.96%
General and Administrative Expense 13.8 M USD -2.7%
Operating Income (Loss) -31.4 M USD -4.93%
Net Income (Loss) Attributable to Parent -31 M USD -3.82%
Earnings Per Share, Basic -0.9 USD/shares +32.3%
Earnings Per Share, Diluted -0.9 USD/shares +32.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Other Assets, Current 539 K USD -10.3%
Assets, Current 24.6 M USD +10.8%
Property, Plant and Equipment, Net 3.33 M USD -20.8%
Operating Lease, Right-of-Use Asset 3.51 M USD -16%
Other Assets, Noncurrent 255 K USD 0%
Assets 33.7 M USD +2.03%
Accounts Payable, Current 924 K USD -55.8%
Accrued Liabilities, Current 895 K USD -40%
Liabilities, Current 5.39 M USD -7.37%
Operating Lease, Liability, Noncurrent 3.83 M USD +10.1%
Liabilities 8.77 M USD -14.9%
Retained Earnings (Accumulated Deficit) -91.2 M USD -49%
Stockholders' Equity Attributable to Parent 17.5 M USD +4.4%
Liabilities and Equity 33.7 M USD +2.03%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.92 M USD -6.45%
Net Cash Provided by (Used in) Financing Activities -277 K USD -151%
Net Cash Provided by (Used in) Investing Activities -71 K USD +83.5%
Common Stock, Shares Authorized 490 M shares 0%
Common Stock, Shares, Issued 43.3 M shares +76.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.27 M USD -12.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.3 M USD +19.4%
Deferred Tax Assets, Gross 20.7 M USD +36.5%
Operating Lease, Liability 4.68 M USD +11.3%
Depreciation 958 K USD +156%
Payments to Acquire Property, Plant, and Equipment 50 K USD -86.5%
Lessee, Operating Lease, Liability, to be Paid 6.1 M USD +10.4%
Operating Lease, Liability, Current 856 K USD +16.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.42 M USD +15.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4 M USD +15.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +8.26%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.42 M USD +7.58%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.22 M USD +20.8%
Deferred Tax Assets, Operating Loss Carryforwards 2.7 M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 891 K USD +16.2%
Additional Paid in Capital 116 M USD +38.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 19.6 M USD +41.3%
Share-based Payment Arrangement, Expense 4.75 M USD +33.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%